Soochow Securities·2025-03-27 01:22Macro Strategy - The report emphasizes that expanding consumer demand is more effective than capacity reduction policies in addressing low inflation, as service prices have dropped to historical lows, which is the core issue of the current price cycle [1][10] - If consumption policies are strengthened, service prices could rise by 2 percentage points, leading to a GDP deflator increase from -0.7% to +0.39%, which would be more beneficial than the effects of capacity reduction [1][10] - Historical comparisons indicate that the current price pressure is primarily demand-driven, with the second industry contributing only 48% to the current low inflation, significantly lower than previous years [1][10] Fixed Income Strategy - The report discusses the introduction of buying and selling government bonds as a new monetary policy tool in China, aimed at managing interest rate risks amid a declining yield environment [2][12] - It highlights that the People's Bank of China has primarily focused on buying government bonds to release liquidity, given the current low inflation environment [2][12] - The effectiveness of these operations will depend on the central bank's ability to provide clear forward guidance to shape market expectations [2][12] Company Analysis: Zhengfan Convertible Bonds - Zhengfan Convertible Bonds are expected to list at a price between 115.63 and 128.82 yuan, with a subscription rate of 0.0048% [3][15] - The bonds have a solid debt protection feature, with a conversion premium rate of approximately 25% anticipated on the first day of listing [3][15] - Zhengfan Technology has shown steady revenue growth, with a compound annual growth rate of 34.10% from 2019 to 2023, and a revenue of 38.35 billion yuan in 2023, reflecting a 41.78% year-on-year increase [3][15] Company Analysis: Kelun-Botai - Kelun-Botai's revenue for 2024 is projected at 19.3 billion yuan, a 25.5% increase year-on-year, with a gross profit of 12.74 billion yuan, up 67.8% [5][16] - The company is expected to see rapid growth in multiple products as they commercialize, with significant clinical data supporting their efficacy [5][16] - Revenue forecasts for 2025 and 2026 have been raised to 17.8 billion and 35.6 billion yuan, respectively, with an expected revenue of 58.9 billion yuan in 2027 [5][16] Company Analysis: China National Materials - China National Materials reported a total revenue of 461.27 billion yuan for 2024, a 0.7% increase, and a net profit of 29.83 billion yuan, up 2.3% [6][19] - The company has shown resilience in its Q4 performance, with overseas engineering and operation maintenance businesses performing well [6][19] - The company plans to distribute a cash dividend of 4.5 yuan per 10 shares, reflecting its commitment to shareholder returns [6][19]